Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade C 18.35 -2.39% -0.45
IMMU closed down 2.39 percent on Wednesday, March 20, 2019, on 62 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical IMMU trend table...

Date Alert Name Type % Chg
Mar 20 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 20 Overbought Stochastic Strength 0.00%
Mar 19 Stochastic Sell Signal Bearish -2.39%
Mar 19 Doji - Bearish? Reversal -2.39%
Mar 19 Wide Bands Range Expansion -2.39%
Mar 19 Overbought Stochastic Strength -2.39%
Mar 18 Pocket Pivot Bullish Swing Setup -2.60%
Mar 18 Wide Bands Range Expansion -2.60%
Mar 18 Overbought Stochastic Strength -2.60%
Mar 15 Pocket Pivot Bullish Swing Setup -1.13%

Older signals for IMMU ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Biotechnology Biopharmaceutical Cancer Immunology Treatment Of Cancer Monoclonal Antibodies Pharmacology Pancreatic Cancer Serious Diseases Non Hodgkin Lymphoma Humanized Antibody Lupus NHL Leukemias Treatment Of Pancreatic Cancer Cd20 Milatuzumab Treatment Of Lupus Treatment Of Non Hodgkin Lymphoma
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.33
52 Week Low 11.55
Average Volume 3,486,687
200-Day Moving Average 20.4249
50-Day Moving Average 15.8876
20-Day Moving Average 16.9125
10-Day Moving Average 17.83
Average True Range 0.814
ADX 24.66
+DI 26.5248
-DI 14.9276
Chandelier Exit (Long, 3 ATRs ) 16.528
Chandelier Exit (Short, 3 ATRs ) 16.262
Upper Bollinger Band 19.4161
Lower Bollinger Band 14.4089
Percent B (%b) 0.79
BandWidth 29.606504
MACD Line 0.8759
MACD Signal Line 0.6801
MACD Histogram 0.1957
Fundamentals Value
Market Cap 2.04 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -12.48
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.87
Resistance 3 (R3) 19.88 19.38 19.61
Resistance 2 (R2) 19.38 19.00 19.38 19.53
Resistance 1 (R1) 18.87 18.76 18.62 18.86 19.44
Pivot Point 18.37 18.37 18.25 18.37 18.37
Support 1 (S1) 17.86 17.99 17.61 17.85 17.26
Support 2 (S2) 17.36 17.75 17.36 17.17
Support 3 (S3) 16.85 17.36 17.09
Support 4 (S4) 16.84